EUVIMEDEUVIMED entdecken
Crossref

Semaglutide for the Treatment of Obesity in Children 6 to

Ania M Jastreboff iD, Nina M Harder-Lauridsen, Michelle Van Name, Antje Körner iD, Aaron S Kelly, Daniel Weghuber, Jens-Christian Holm, Christine Frithioff-Bøjsøe, Shilpa Middolu, Tina Buch, Martin Wabitsch iD, STEP Young Investigators

New England Journal of Medicine · 16.11.2026

DOI: 10.1056/nejmoa2604058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New England Journal of Medicine, online erschienen am 16.11.2026. Verfasst von Ania M Jastreboff und 11 weiteren Autor:innen. Beteiligte Einrichtung: Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Novo Nordisk.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Childhood obesity is a chronic, neurometabolic disease with limited options for medical treatments that are efficacious and durable. Once-weekly subcutaneous semaglutide is approved for the treatment of obesity in adolescents and adults, but data for its use in young children are lacking. METHODS: We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving children (6 to

Autor:innen und Institutionen

  • Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT.
  • Section of Pediatric Endocrinology, Department of Pediatrics, Yale School of Medicine, Yale University, New Haven, CT.
  • Yale Obesity Research Center (Y-Weight), Yale School of Medicine, Yale University, New Haven, CT.
  • Novo Nordisk, Søborg, Denmark.
  • Department of Pediatrics, Yale School of Medicine, Yale University, New Haven, CT.
  • University Hospital for Children and Adolescents, Center for Pediatric Research and Helmholtz Institute for Metabolic, Obesity, and Vascular Research (HI-MAG) of Helmholtz Munich at Leipzig University and Leipzig Univer…

ORCID-Profile: Ania M Jastreboff, Antje Körner, Martin Wabitsch

Förderung

  • Novo Nordisk

Zitieren

APA

Jastreboff, A. M., Harder-Lauridsen, N. M., Van Name, M., Körner, A., Kelly, A. S., Weghuber, D., Holm, J. C., Frithioff-Bøjsøe, C., Middolu, S., Buch, T., Wabitsch, M., & STEP Young Investigators (2026). Semaglutide for the Treatment of Obesity in Children 6 to. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2604058

Vancouver

Jastreboff AM, Harder-Lauridsen NM, Van Name M, Körner A, Kelly AS, Weghuber D, et al. Semaglutide for the Treatment of Obesity in Children 6 to. New England Journal of Medicine. 2026. doi:10.1056/nejmoa2604058

BibTeX
@article{Jastreboff2026,
  author = {Jastreboff, Ania M and Harder-Lauridsen, Nina M and Van Name, Michelle and Körner, Antje and Kelly, Aaron S and Weghuber, Daniel and Holm, Jens-Christian and Frithioff-Bøjsøe, Christine and Middolu, Shilpa and Buch, Tina and Wabitsch, Martin and STEP Young Investigators, STEP Young Investigators},
  title = {Semaglutide for the Treatment of Obesity in Children 6 to},
  journal = {New England Journal of Medicine},
  year = {2026},
  doi = {10.1056/nejmoa2604058}
}
Kostenlos starten →